For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
New FDA lab tests rule could bankrupt small labs
Yesterday the Food and Drug Administration (FDA) announced that on May 6 it will promulgate a rule under its authority to regulate medical devices.
National Review
The Return of the Cadillac Tax?
Like the phoenix, a key piece of the Affordable Care Act has risen from the ashes, resurrected, believe it or not, by the Republican Study Committee…
Blog
Free the Economy podcast: Paying for organs with Pete Jaworski
In this week’s episode we cover the future of AI and employment, why we shouldn’t trust Chinese economic statistics, and how the…
Search Posts
Op-Eds
Sympathy for the Mosquito?
“Save Our Mosquitoes,” isn't a plea one expects to see these days with the mosquito-borne West Nile Virus killing hundreds and making thousands…
News Release
Soso R. Whaley Featured in The American Spectator
Click here to read full story. <?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> <?xml:namespace prefix =…
News Release
Enter and Win!
Name that film!<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> For a month, you’ve been reading about Soso’s…
News Release
Media Conference Call, Wed., May 5
Contact: Jody Clarke, 202.331.2252<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> Washington, DC, May 4, 2004—Her quest started…
Op-Eds
“I Love Humanity; It’s People I Can’t Stand”
This is part 2 of a two-part series. To read part 1, please click here.<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” />…
Op-Eds
Biotech’s Antagonists
This is part 1 of a two-part series. To read part 2, please click here.<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” />…